DCM
AMLX icon

DAFNA Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

DAFNA Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-122,547
Closed -$1.8M – 73
2023
Q4 		$1.8M Hold
122,547
– – 0.43% 44
2023
Q3 		$2.24M Buy
+122,547
New +$2.59M 0.7% 35

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

DAFNA Capital Management's AMLX Position: Q1 2024 in Review

DAFNA Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 122,547 shares — an estimated $1.8M sold.

DAFNA Capital Management first reported a position in AMLX in Q3 2023 and held it in 2 quarters. The position peaked at $2.24M in Q3 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • DAFNA Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 122,547 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $1.8M.
  • DAFNA Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • DAFNA Capital Management's Amylyx Pharmaceuticals position peaked at $2.24M in Q3 2023.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.